OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial.

Sun J, Wang L, Wu Y, Humphrey S, Chen SG, McGillivray W, Huang SH, Zhang Y, Pan G, Foley C, Lee E, Chang-Lin JE, Faletto DL, Patel V, Bowen B, Brin MF

Open source

DOI
10.1093/asj/sjaf204
Published
2026 Apr 7
Container
Aesthetic surgery journal
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/asj/sjaf204,
  title = {OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial.},
  author = {Sun J and Wang L and Wu Y and Humphrey S and Chen SG and McGillivray W and Huang SH and Zhang Y and Pan G and Foley C and Lee E and Chang-Lin JE and Faletto DL and Patel V and Bowen B and Brin MF},
  year = {2026},
  journal = {Aesthetic surgery journal},
  doi = {10.1093/asj/sjaf204},
  url = {https://doi.org/10.1093/asj/sjaf204}
}

RIS

TY  - JOUR
TI  - OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial.
AU  - Sun J
AU  - Wang L
AU  - Wu Y
AU  - Humphrey S
AU  - Chen SG
AU  - McGillivray W
AU  - Huang SH
AU  - Zhang Y
AU  - Pan G
AU  - Foley C
AU  - Lee E
AU  - Chang-Lin JE
AU  - Faletto DL
AU  - Patel V
AU  - Bowen B
AU  - Brin MF
PY  - 2026
JO  - Aesthetic surgery journal
DO  - 10.1093/asj/sjaf204
UR  - https://doi.org/10.1093/asj/sjaf204
ER  - 

APA

J, S., L, W., Y, W., S, H., SG, C., W, M., SH, H., Y, Z., G, P., C, F., E, L., JE, C., DL, F., V, P., B, B., & MF, B. (2026). OnabotulinumtoxinA Treatment for Masseter Muscle Prominence: 6-Month Safety and Efficacy Results, Including Patient-Reported Outcomes, From a Phase 3, Randomized, Placebo-Controlled, Multiregional Trial.. Aesthetic surgery journal. https://doi.org/10.1093/asj/sjaf204

Source records